Table 2 Studies investigating the roles of (P) RR in different cancers

Shibayama et al., 2015 [11]

Pancreatic ductal adenocarcinoma (PDAC)

PK-8, PCI-35, BxPC-3, PK-1, PANC-1 and MIAPaCa-2

Wnt/β-catenin pathway

Higher (P) RR expression: higher proliferation ability and less apoptosis of cancer cells; enhanced Wnt/β-catenin activity

Arundhathi et al., 2016 [32]

PDAC

Panc-1, ASPC, BXPC-3, HPAC, and MIAPaCa-2

MAPK/ERK and PI3K/AKT/mTOR pathways

Higher (P) RR expression: more advanced disease; enhanced MAPK/ERK and PI3K/AKT/mTOR signaling activity

Kouchi et al., 2017 [13]

Glioma

U251MG, U87MG, and T98G

Wnt/β-catenin pathway

Higher (P) RR expression: more advanced disease; higher proliferation ability and less apoptosis of cancer cells; enhanced Wnt/β-catenin activity

Juillerat-Jeanneret et al., 2004 [38]

Glioblastoma (GBM)

LN18 and LNZ308

RAS pathway

Higher (P) RR expression: more advanced disease; higher proliferation ability of cancer cells; enhanced RAS activity

Wang et al., 2019 [10]

Colorectal cancer (CRC)

DLD-1 and HCT116

Wnt/β-catenin pathway

Higher (P) RR expression: higher proliferation ability and less apoptosis of cancer cells; enhanced Wnt/β-catenin activity

Maider et al., 2019 [44]

CRC

Not applicable (only clinical samples were used)

Not applicable

Higher (P) RR expression: more advanced disease; worse prognosis (e.g. 5- or 10- year survival)

Ohba et al., 2014 [14]

Breast cancer

MCF-7, T47D, SK-BR-3 and MDA-MB-231

MAKP/ERK pathway and V-ATPase

Higher (P) RR expression: higher proliferation ability of cancer cells

Yamamoto et al., 2013 [15]

Aldosterone-producing adenoma (APA)

H295R and HAC15

Not mentioned

Higher (P) RR expression: higher proliferation ability of cancer cells and more aldosterone secretion

Delforce et al., 2017 [28]

Endometrial cancer

MCF-7

RAS

Higher (P) RR expression: higher proliferation ability of cancer cells, possibility of cancer spread and RAS activity